Navigation Links
Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)
Date:4/7/2009

(orgasm with reduced semen), an expected effect of selective alpha blockers. Rates of discontinuing therapy due to retrograde ejaculation were low. The second most commonly-reported adverse event was dizziness. The incidence of treatment-related dizziness was low and only slightly higher among RAPAFLO(TM) than placebo-treated patients.

Previously presented data included information that in clinical trials RAPAFLO(TM) was administered with a single dose of medications for erectile dysfunction in healthy male subjects (N=24) and that there were no reported events of symptomatic orthostatis or dizziness.

RAPAFLO(TM) was originally developed by Kissei Pharmaceutical Co., Ltd. in Japan, where RAPAFLO(TM) is the BPH market leader, and licensed to Watson for the US, Canada and Mexico markets.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. is a global leader in the development and distribution of pharmaceuticals with a broad portfolio of generic products and a specialized portfolio of branded pharmaceuticals focused on Urology, Gynecology and Nephrology (Medical).

In the U.S., the Watson Brand portfolio includes RAPAFLO(TM), GELNIQUE, TRELSTAR(R) LA, TRELSTAR(R) Depot, Ferrlecit(R), INFeD(R), and Oxytrol(R). In addition, Watson markets the following brands under co-promotion agreements: AndroGel(R), with Solvay Pharmaceuticals, Inc.; Tri-Luma(R) Cream, with Galderma Laboratories; and Femring(R), with Warner Chilcott Limited. The Watson pipeline portfolio includes a number of products, including a six-month formulation of TRELSTAR(R) for the treatment of advanced prostate cancer, which is currently under review by the FDA; URACYST(R), under development for cystitis; and a novel oral contraceptive.

For press releases and other company information, visit the Watson Web site at http://www.watson.
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder
2. Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia
3. Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder
4. Watson Launches Generic Biaxin(R) XL
5. Cephalon Announces Positive Results from a Phase Three Study of NUVIGIL in Jet Lag Disorder
6. Cynosure Announces Presentation of Favorable Results from Post-Marketing Studies of Smartlipo MPX
7. Pharmaxis Announces Milestone in Phase III Trial for Cystic Fibrosis
8. Schering-Plough Announces Results of the Early ACS Trial
9. Hyperion Therapeutics Announces Results for Phase II Study in Urea Cycle Disorders
10. Lilly Announces Inconclusive Phase II Study Results for mGlu2/3 at the International Congress on Schizophrenia Research
11. Impulse Dynamics Announces Pivotal Results at the American College of Cardiology Annual Meeting Late-Breaking Session
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 2014  Publicis Groupe customer engagement agency ... and Healthcare Industry Group Leader, has been featured in ... most inspiring people in the life-sciences industry. Those chosen ... development, marketing, technology, creativity, strategy and medicine. ... partner in its leading Rosetta Consulting practice. In 2012, ...
(Date:8/21/2014)... Aug. 21, 2014  Decision Resources Group finds ... Brazil and ... and commonly prescribe long-acting beta-agonist (LABA)- and long-acting ... so within current severe cost/coverage constraints. Therefore, new ... expected to launch in these countries—which will considerably ...
(Date:8/21/2014)... 21, 2014 /PRNewswire-iReach/ -- ScriptPro has been certified ... its Common Security Framework (CSF). According to ... Manager, "We appreciate this rigorous, top-to-bottom audit. Security-minded ... this certification signifies. Our business partners need to ... CSF CERTIFICATION PROCESS: ScriptPro,s internal security processes and ...
Breaking Medicine Technology:Shannon Hartley Shines in PharmaVOICE 100 2Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 2Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 3ScriptPro Achieves HITRUST Certification 2
... Johnson & Johnson (NYSE: JNJ ) today ... & Diagnostics (MD&D) and Sheri McCoy, currently Worldwide Chairman, ... Committee and join William C. Weldon, Chairman of the ... of the Chairman.  Both appointments are effective January 3, ...
... LAKE FOREST, Ill., Dec. 15, 2010 RoundTable ... focused exclusively on the healthcare industry, announced today ... to sell one of its portfolio companies, Clinical ... private investment firm representing Pritzker family interests.  Terms ...
Cached Medicine Technology:Johnson & Johnson Announces Executive Appointments: Alex Gorsky, Vice Chairman, Executive Committee Sheri McCoy, Vice Chairman, Executive Committee 2Johnson & Johnson Announces Executive Appointments: Alex Gorsky, Vice Chairman, Executive Committee Sheri McCoy, Vice Chairman, Executive Committee 3RoundTable Healthcare Partners Announces Sale of Clinical Innovations, LLC to The Pritzker Group 2
(Date:8/22/2014)... Bcl-2-like protein 11 (BIM) deletion in advanced ... shorter progression free survival (PFS) in epidermal growth ... chemotherapy treated Asian patients. Also, BIM deletion independently ... , The BIM protein can activate the programmed ... in cells. BIM deletion has been detected in ...
(Date:8/22/2014)... Rheumatoid arthritis (RA), a complex autoimmune disease that ... patients to not only cope with pain, disability ... as disrupted work, family life and marital functioning. ... residual pain and disability is common. In addition, ... high cost or side effects. Because of this, ...
(Date:8/22/2014)... (PRWEB) August 22, 2014 Advancements ... for some clinical applications due to their cost-effectiveness, ... emerging innovations in ultrasound, such as the evolution ... expected to keep the market moving throughout 2014 ... mobility can enhance not only the point-of-care (POC) ...
(Date:8/22/2014)... Sac, Wisconsin (PRWEB) August 22, 2014 ... System for Plantar Fasciitis, an exciting new product that ... allows you to stay active while you heal. The ... This is truly a new technology – it is ... affordable. , FasciaDerm® PFTape™ System for Plantar Fasciitis ...
(Date:8/22/2014)... intensive effort to sterilize feral cats reduced the number of ... a new study reveals. "We investigated whether we ever ... control," Dr. Julie Levy, a professor of shelter medicine at ... a university news release. "Neutering a few cats ... "so we wanted to pick a focused area and throw ...
Breaking Medicine News(10 mins):Health News:Deletion predicts survival in advanced non-small cell lung cancer 2Health News:Study shows cognitive-behavioral coping skills training has positive effects on rheumatoid arthritis 2Health News:Global Top Ultrasound Market Suppliers Assessed in New VPG Research Report Available at MarketPublishers.com 2Health News:Global Top Ultrasound Market Suppliers Assessed in New VPG Research Report Available at MarketPublishers.com 3Health News:Mueller Introduces FasciaDerm® PFTape™ System for Plantar Fasciitis 2Health News:Neutering Project Curbed Feral Cat Population 2
... a potential heart attack risk? According to a recent study, ... with the strengthening of the US economy., ,Christopher Ruhm, ... Greensboro wrote in his study that there is a pronounced ... economy grows further with no improvement in the rate of ...
... to a study conducted by the University of Erfurt ... willing to inflict financial pain to achieve// collective gain. ... ,Researchers have found that groups in ... were more popular than groups without this option. Though ...
... According to experts approximately 6,000 plus trampolining fractures were ... for new safety guidelines// are needed to stem the ... in a study has found a "worrying trend" in ... in the home. ,The Royal Berkshire in ...
... doesn’t seem to have learnt its lessons yet, because there ... of AIDS/HIV//. Next only to South Africa with the highest ... million mark as per statistics in 2003, very little has ... AIDS/HIV cases, according to Prof Suzanne Crowe, Deputy Chairperson of ...
... Pharma has come up with a new neupro skin patch ... It is said to offer relief to patients// in the ... mimics the effects of a naturally occurring brain chemical, which ... ,The Parkinson's Disease Society said that the patch would aid ...
... It’s learning time for countries, and Vietnam’s tryst with ... management//. Vietnamese Farmers appear to know much more about ... their counterparts in Europe and Africa. Not surprising, since ... the onslaught of bird-flu, which in 2003 had claimed ...
Cached Medicine News:Health News:Competitive Advantage Are Attained In Which Freeloaders Are Punished 2Health News:Competitive Advantage Are Attained In Which Freeloaders Are Punished 3Health News:Competitive Advantage Are Attained In Which Freeloaders Are Punished 4Health News:Be cautious while on the Trampoline 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: